The role of biomarkers in the management of patients with rheumatoid arthritis

Current Rheumatology Reports

Volumn 11, Issue 5, 2009, Pages 371-377

  Emery, Paul ^a   Nam, Jackie ^b   Villeneuve, Edith ^b  

^a CHAPEL ALLERTON HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIPERINUCLEAR FACTOR; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARBOXY TERMINAL TELOPEPTIDE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GAMMA INTERFERON; HLA DR ANTIGEN; HYDROXYCHLOROQUINE; INFLIXIMAB; INTERLEUKIN 1BETA; INTERLEUKIN 6; KERATIN ANTIBODY; METHOTREXATE; MONOCYTE CHEMOTACTIC PROTEIN 1; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PLACEBO; PREDNISOLONE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA;

BONE EROSION; BONE TURNOVER; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; COLLAGEN DEGRADATION; DISEASE ACTIVITY; DRUG DOSE COMPARISON; ERYTHROCYTE SEDIMENTATION RATE; GENETIC ANALYSIS; HUMAN; INFLAMMATION; JOINT DESTRUCTION; LOW DRUG DOSE; OUTCOME ASSESSMENT; PROGNOSIS; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; DISEASE PROGRESSION; HEALTH STATUS; HUMANS; INDIVIDUALIZED MEDICINE; MONITORING, PHYSIOLOGIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 70449685940     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-009-0053-x     Document Type: Review

References (50)

1. R. Maini E.W. St Clair F. Breedveld, et al. 1999 Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group Lancet 354 1932 1939 10622295 10.1016/S0140-6736(99)05246-0 1:CAS:528:DC%2BD3cXit1Oquw%3D%3D
2. L. Klareskog D. van der Heijde J.P. de Jager, et al. 2004 Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial Lancet 363 675 681 15001324 10.1016/S0140-6736(04)15640-7 1:CAS:528:DC%2BD2cXhs12jur4%3D (Pubitemid 38296553)
3. A.K. Brown P.G. Conaghan Z. Karim, et al. 2008 An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis Arthritis Rheum 58 2958 2967 18821687 10.1002/art.23945 1:STN:280:DC%2BD1cnkvFeltg%3D%3D
4. J.S. Smolen D. Aletaha J. Grisar, et al. 2008 The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now? Arthritis Res Ther 10 208 18557991 10.1186/ar2418
5. P. Emery I.B. McInnes R. van Vollenhoven M.C. Kraan 2008 Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis Rheumatology (Oxford) 47 392 398 10.1093/rheumatology/ kem257 1:CAS:528:DC%2BD1cXmslKhtro%3D
6. H. Marotte B. Pallot-Prades L. Grange, et al. 2006 The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population Ann Rheum Dis 65 342 347 16096333 10.1136/ard.2005.037150 1:CAS:528:DC%2BD28XisFCjtL0%3D (Pubitemid 43268223)
7. J.K. de Vries-Bouwstra Y.P. Goekoop-Ruiterman K.N. Verpoort, et al. 2008 Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies Arthritis Rheum 58 1293 1298 18438829 10.1002/art.23439 (Pubitemid 351705918)
8. L.A. Criswell R.F. Lum K.N. Turner, et al. 2004 The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept Arthritis Rheum 50 2750 2756 15457442 10.1002/art.20469 1:CAS:528:DC%2BD2cXoslGgs7s%3D (Pubitemid 39209511)
9. C. Potter K.L. Hyrich A. Tracey, et al. 2009 Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis Ann Rheum Dis 68 69 74 18375541 10.1136/ard.2007.084715 1:CAS:528:DC%2BD1MXhslOlt70%3D
10. L. Padyukov J. Lampa M. Heimburger, et al. 2003 Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis Ann Rheum Dis 62 526 529 12759288 10.1136/ard.62.6.526 1:CAS:528: DC%2BD3sXkslKqu7w%3D (Pubitemid 36606284)
11. J.A. Pinto I. Rego M. Rodriguez-Gomez, et al. 2008 Polymorphisms in genes encoding tumor necrosis factor-alpha and HLA-DRB1 are not associated with response to infliximab in patients with rheumatoid arthritis J Rheumatol 35 177 178 18176993
12. Szodoray P, Szabo Z, Kapitany A, et al.: Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis. Autoimmun Rev 2009 May 7 (Epub ahead of print).
13. L.B. Hughes M.I. Danila S.L. Bridges 2009 Recent advances in personalizing rheumatoid arthritis therapy and management Personalized Medicine 6 159 170 10.2217/17410541.6.2.159 1:CAS:528:DC%2BD1MXjtFanu70%3D
14. R.M. Plenge L.A. Criswell 2008 Genetic variants that predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis: current challenges and future directions Curr Opin Rheumatol 20 145 152 18349743 10.1097/BOR.0b013e3282f5135b 1:CAS:528:DC%2BD1cXjslWlu7g%3D (Pubitemid 351339885)
15. M. Bukhari M. Lunt B.J. Harrison, et al. 2002 Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: results from the Norfolk Arthritis Register Study, a large inception cohort Arthritis Rheum 46 906 912 11953966 10.1002/art.10167 1:STN:280:DC%2BD383hs1Gkug%3D%3D (Pubitemid 34303801)
16. O. Meyer C. Labarre M. Dougados, et al. 2003 Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage Ann Rheum Dis 62 120 126 12525380 10.1136/ard.62.2.120 1:CAS:528:DC%2BD3sXhtlSiu7Y%3D (Pubitemid 36135386)
17. E. Berglin T. Johansson U. Sundin, et al. 2006 Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset Ann Rheum Dis 65 453 458 16176994 10.1136/ard.2005.041376 1:STN:280:DC%2BD287ktFKjsA%3D%3D
18. W.H. Bos G.M. Bartelds G.J. Wolbink, et al. 2008 Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis J Rheumatol 35 1972 1977 18785316 1:CAS:528:DC%2BD1cXhtlWit7nL
19. A. Bruns P. Nicaise-Roland G. Hayem, et al. 2009 Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis Joint Bone Spine 76 248 253 19208451 10.1016/j.jbspin.2008. 09.010
20. M. Cuchacovich D. Catalan E. Wainstein, et al. 2008 Basal anticyclic citrullinated peptide (anti-CCP) antibody levels and a decrease in anti-CCP titres are associated with clinical response to adalimumab in rheumatoid arthritis Clin Exp Rheumatol 26 1067 1073 19210871 1:STN:280: DC%2BD1M7jsFCrsQ%3D%3D
21. K. Visser K.N. Verpoort H. van Dongen, et al. 2008 Pretreatment serum levels of anti-cyclic citrullinated peptide antibodies are associated with the response to methotrexate in recentonset arthritis Ann Rheum Dis 67 1194 1195 18621971 10.1136/ard.2008.088070 1:STN:280:DC%2BD1cvksVOmtg%3D%3D
22. R.M. Nakamura 2000 Progress in the use of biochemical and biological markers for evaluation of rheumatoid arthritis J Clin Lab Anal 14 305 313 11138614 10.1002/1098-2825(20001212)14:6<305::AID-JCLA10>3.0.CO;2-P 1:CAS:528:DC%2BD3cXptVagtb4%3D
23. J.S. Smolen D.M. Van Der Heijde E.W. St Clair, et al. 2006 Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial Arthritis Rheum 54 702 710 16508926 10.1002/art.21678 1:CAS:528: DC%2BD28XjtV2ls74%3D
24. M.H. Buch Y. Seto S.J. Bingham, et al. 2005 C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept Arthritis Rheum 52 42 48 15641046 10.1002/art.20711 1:CAS:528: DC%2BD2MXht1KisLc%3D (Pubitemid 40129231)
25. P. Emery C. Gabay M. Kraan J. Gomez-Reino 2007 Evidencebased review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis Rheumatol Int 27 793 806 17505829 10.1007/s00296-007-0357-y 1:CAS:528:DC%2BD2sXmtlGkt7s%3D (Pubitemid 46906651)
26. M.H. Buch R.J. Reece M.A. Quinn, et al. 2008 The value of synovial cytokine expression in predicting the clinical response to TNF antagonist therapy (infliximab) Rheumatology (Oxford) 47 1469 1475 10.1093/rheumatology/ ken261 1:CAS:528:DC%2BD1cXhtFCisr7L
27. S. Fabre A.M. Dupuy N. Dossat, et al. 2008 Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis Clin Exp Immunol 153 188 195 18549443 10.1111/j.1365-2249. 2008.03691.x 1:CAS:528:DC%2BD1cXhtVOnu7%2FI (Pubitemid 351989164)
28. D.M. Gerlag P.P. Tak 2008 Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials Best Pract Res Clin Rheumatol 22 311 323 18455687 10.1016/j.berh.2008.02.002 1:CAS:528:DC%2BD1cXls12gtb4%3D (Pubitemid 351606951)
29. M.C. Kraan J.J. Haringman H. Weedon, et al. 2004 T cells, fibroblast-like synoviocytes, and granzyme B+ cytotoxic cells are associated with joint damage in patients with recent onset rheumatoid arthritis Ann Rheum Dis 63 483 488 15082476 10.1136/ard.2003.009225 1:STN:280:DC%2BD2c7osFSjsg%3D%3D (Pubitemid 38530189)
30. B. Bresnihan D.M. Gerlag T. Rooney, et al. 2007 Synovial macrophages as a biomarker of response to therapeutic intervention in rheumatoid arthritis: standardization and consistency across centers J Rheumatol 34 620 622 17343309
31. A. Kavanaugh S. Rosengren S.J. Lee, et al. 2008 Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results Ann Rheum Dis 67 402 408 17644541 10.1136/ard.2007.074229 1:CAS:528:DC%2BD1cXjs1ejsLs%3D (Pubitemid 351281278)
32. K. Vos R.M. Thurlings C.A. Wijbrandts, et al. 2007 Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis Arthritis Rheum 56 772 778 17328049 10.1002/art.22400 1:CAS:528: DC%2BD2sXjs1ylu7o%3D (Pubitemid 46399424)
33. F. Humby A. Manzo B. Kirkham C. Pitzalis 2007 The synovial membrane as a prognostic tool in rheumatoid arthritis Autoimmun Rev 6 248 252 17317617 10.1016/j.autrev.2006.08.013 (Pubitemid 46290648)
34. S. Dass A.C. Rawstron E.M. Vital, et al. 2008 Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis Arthritis Rheum 58 2993 2999 18821683 10.1002/art.23902 1:CAS:528: DC%2BD1cXht12rur%2FL
35. C.H. Burgoyne S.L. Field A.K. Brown, et al. 2008 Abnormal T cell differentiation persists in patients with rheumatoid arthritis in clinical remission and predicts relapse Ann Rheum Dis 67 750 757 17644540 10.1136/ard.2007.073833 1:CAS:528:DC%2BD1cXnvFOltL0%3D (Pubitemid 351829373)
36. S. Young-Min T. Cawston N. Marshall, et al. 2007 Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers Arthritis Rheum 56 3236 3247 17907159 10.1002/art.22923 1:CAS:528:DC%2BD2sXht12rtLnO (Pubitemid 47585418)
37. S. Visvanathan J.C. Marini J.S. Smolen, et al. 2007 Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis J Rheumatol 34 1465 1474 17552048 1:CAS:528:DC%2BD2sXptVCkurg%3D
38. M.J. Green A.K. Gough J. Devlin, et al. 2003 Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis Rheumatology (Oxford) 42 83 88 10.1093/rheumatology/keg037 1:CAS:528:DC%2BD3sXovFamsQ%3D%3D (Pubitemid 36131572)
39. I. Tchetverikov L.R. Lard J. DeGroot, et al. 2003 Matrix metal-loproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis Ann Rheum Dis 62 1094 1099 14583574 10.1136/ard.62.11.1094 1:CAS:528:DC%2BD3sXpsVSksL0%3D (Pubitemid 37323575)
40. P. Garnero E. Gineyts S. Christgau, et al. 2002 Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis Arthritis Rheum 46 21 30 11817593 10.1002/1529-0131(200201) 46:1<21::AID-ART10061>3.0.CO;2-Q 1:CAS:528:DC%2BD38Xht1Wlurk%3D (Pubitemid 34121647)
41. S.M. Verstappen A.R. Poole M. Ionescu, et al. 2006 Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers: an evaluation from 1 to 4 years after diagnosis Arthritis Res Ther 8 R31 16507130 10.1186/ar1882 1:CAS:528:DC%2BD28XhvFWgsLg%3D
42. R. Landewe P. Geusens M. Boers, et al. 2004 Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis Arthritis Rheum 50 1390 1399 15146408 10.1002/art.20222 1:CAS:528:DC%2BD2cXkvFyktbk%3D (Pubitemid 38608060)
43. R.H. Mullan C. Matthews B. Bresnihan, et al. 2007 Early changes in serum type II collagen biomarkers predict radiographic progression at one year in inflammatory arthritis patients after biologic therapy Arthritis Rheum 56 2919 2928 17763421 10.1002/art.22843 1:CAS:528:DC%2BD2sXht1GgtbzL (Pubitemid 47502738)
44. M. Crnkic B. Mansson L. Larsson, et al. 2003 Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept Arthritis Res Ther 5 R181 R185 12823852 10.1186/ar760 1:CAS:528:DC%2BD3sXjvVGhsb0%3D
45. G. Morozzi M. Fabbroni F. Bellisai, et al. 2007 Low serum level of COMP, a cartilage turnover marker, predicts rapid and high ACR70 response to adalimumab therapy in rheumatoid arthritis Clin Rheumatol 26 1335 1338 17285224 10.1007/s10067-006-0520-y 1:STN:280:DC%2BD2sznvVyruw%3D%3D (Pubitemid 47034192)
46. H. Marotte E. Gineyts P. Miossec P.D. Delmas 2009 Effects of infliximab therapy on biological markers of synovium activity and cartilage breakdown in patients with rheumatoid arthritis Ann Rheum Dis 68 1197 1200 18713784 10.1136/ard.2008.096057 1:CAS:528:DC%2BD1MXovVCms74%3D
47. P.P. Geusens R.B. Landewe P. Garnero, et al. 2006 The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction Arthritis Rheum 54 1772 1777 16736519 10.1002/art.21896 1:CAS:528:DC%2BD28Xms1Sjtbw%3D (Pubitemid 43877926)
48. M. Hakala J. Risteli S. Aman, et al. 2008 Combination drug strategy in recent-onset rheumatoid arthritis suppresses collagen I degradation and is associated with retardation of radiological progression Scand J Rheumatol 37 90 93 18415764 10.1080/03009740701753689 1:CAS:528:DC%2BD1cXkvFOlsr8%3D
49. S.W. Syversen G.L. Goll D. van der Heijde, et al. 2009 Cartilage and bone biomarkers in rheumatoid arthritis: prediction of 10-year radiographic progression J Rheumatol 36 266 272 19132792 10.3899/jrheum.080180 1:CAS:528:DC%2BD1MXjt1Cmtr0%3D
50. S.O. Keeling R. Landewe D. van der Heijde, et al. 2007 Testing of the preliminary OMERACT validation criteria for a biomarker to be regarded as reflecting structural damage endpoints in rheumatoid arthritis clinical trials: the example of C-reactive protein J Rheumatol 34 623 633 17343310 1:CAS:528:DC%2BD2sXktVCisrc%3D (Pubitemid 46364022)